Vaxart Provides Merger Update
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--
Vaxart, Inc., a clinical-stage biotechnology company developing oral
recombinant vaccines that are administered by tablet rather than by
injection, announced today it has reached an understanding with the CAS
Group under which East Hill, a major shareholder in Aviragen, will
support the merger between Vaxart and Aviragen.
“We are committed to creating significant value for all our shareholders
as evidenced by the amended terms of the merger that were recently
announced,” said Wou...